Intrauterine levonorgestrel delivered by a frameless system, combined with systemic estrogen: Acceptability and endometrial safety after 3 years of use in peri- and postmenopausal women

Gynecological Endocrinology

Volumn 20, Issue 6, 2005, Pages 336-342

  Wildemeersch, Dirk ^a,e   Janssens, Dirk ^b   Schacht, Etienne ^c   Pylyser, Kris ^d   De Wever, Nathalie ^d  

^a Gynecological Outpatient Clinic and IUD Training Center   (Belgium)

^b Gynecologische Dienst   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d SINT AUGUSTINUS HOSPITAL   (Belgium)

^e NONE   (Belgium)

Author keywords

Hormone therapy; Intrauterine drug delivery system; Levonorgestrel; Perimenopause; Postmenopause; Progestins; Progestogens

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN; LEVONORGESTREL;

ABDOMINAL PAIN; ACNE; ADULT; AGED; ARTICLE; BLOATING; BREAST CANCER; BREAST TENDERNESS; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CLIMACTERIUM; CLINICAL TRIAL; DECIDUALIZATION; DEPRESSION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SAFETY; ENDOMETRIUM ATROPHY; ENDOMETRIUM BIOPSY; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; HEADACHE; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; INTRAUTERINE DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MOOD DISORDER; MOOD SWING; OSTEOLYSIS; PATIENT SATISFACTION; PELVIC INFLAMMATORY DISEASE; PERFORATION; POSTMENOPAUSE; PRIORITY JOURNAL; SYSTEMIC THERAPY; TRANSVAGINAL ECHOGRAPHY;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; ENDOMETRIUM; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; LONGITUDINAL STUDIES; MENOPAUSE; MIDDLE AGED; PATIENT SATISFACTION; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 22144463207     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/09513590500099156     Document Type: Article

References (40)

1. The North American Menopause Society (NAMS). Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society. Menopause 2003;10:113-132.
2. Riphagen FE. Intrauterine application of progestins in hormone replacement therapy: a review. Climacteric 2000;3:199-211.
3. Bain C, Kitchener HC. 1998. Post-menopausal bleeding. In: Cameron IT, Fraser IS, Smith SK, editors. Clinical disorders of the endometrium and menstrual cycle. Oxford: Oxford University Press. pp. 266-278.
4. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of 'untreated' hyperplasia in 170 patients. Cancer 1985,56:403-412.
5. Lethaby A, Farquhar C, Sarkis A, Roberts H, Jepson R, Barlow D. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and endometrial bleeding. Cochrane Database Syst Rev 2000;2:CD00402.
6. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J Am Med Assoc 2002;288:321-333.
7. Li CI, Malone KE, Porter PL, Weiss NS, Tang M-TC, Cushing-Haugen KL, Daling JR. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. J Am Med Assoc 2003;289:3254-3263.
8. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan M, Cyr MG, Thomson CA, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. J Am Med Assoc 2003;289:3243-3253.
9. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
10. Weiss LK, Burkman RT, Cushing-Haugen KL, Voigt LF, Simon MS, Daling JR, Norman SA, Bernstein L, Ursin G, Marchbanks PA, et al. Hormone replacement therapy regimens and breast cancer risk (1). Obstet Gynecol 2002;100:1148-1158.
11. Olsson HL, Ingvar C, Bladstrom A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003;97:1387-1392.
12. Nilsson CG, Lähteenmaki PLA, Luukainen T, Robertson DN. Sustained intrauterine release of levonorgestrel over five years. Fert Steril 1986;45:805-807.
13. Andersson K, Mattsson LA, Rybo G, Stadberg E. Intrauterine release of levonorgestrel - a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992;79:963-967.
14. Wildemeersch D, Schacht E. Endometrial suppression with a new 'frameless' levonorgestrel releasing intrauterine system in perimenopausal and postmenopausal women: a pilot study. Maturitas 2000;36:63-68.
15. Mirena®. Product Monograph. Finland: Schering AG and Leiras Oy; 2002.
16. World Health Organization. Medical eligibility criteria for contraceptive use. Geneva: WHO; 2000.
17. Fleischer AC, Kalemeris GC, Machin JE, Entman SS, James AE. Sonographic depiction of normal and abnormal endometrium with histopathologic correlation. J Ultrasound Med 1986;5:445-452.
18. Hendrickson MR, Kempson RL. 1980. Surgical pathology of the uterine corpus. In: Major problems in pathology. Vol. 12. Philadelphia: WB Saunders. pp. 99-158.
19. SAS Institute Inc. SAS user's guide: basics. Version 5 edition. Cary (NC): SAS Institute Inc.; 1985.
20. Tietze C, Lewit S. Recommended procedures for the statistical evaluation of intrauterine contraception. Stud Fam Plann 1972;4:35-42.
21. Farley TMM. Life-table methods for contraceptive research. Stat Med 1986;5:475-489.
22. Sarrel. PM. How progestins compromise the cardioprotective effects of estrogens. Menopause 1995;2:187-190.
23. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 1998;280:605-613.
24. Wollter-Svensson LO, Stadberg E, Andersson K, Matsson LA, Odlind V, Persson I. Intrauterine administration of levonorgestrel in two low doses in HRT. A randomized clinical trial during one year: effects on lipid and lipoprotein metabolism. Maturitas 1995;22:199-205.
25. Raudaskoski T, Tapanainen J, Tomás E, Luotola H, Pekonen F, Ronni-Sivula H, Timonen H, Riphagen F, Laatikainen T. Intrauterine 10 μg and 20 μg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. Br J Obstet Gynecol 2002;109:136-144.
26. Wildemeersch D, Dhont M. Treatment of non atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system. Am J Obstet Gynecol 2003;138:1297-1298.
27. Nilsson CG, Luukainen T, Arco H. Endometrial morphology of women using a D-norgestrel-releasing intrauterine device. Fertil Steril 1978;29:397-401.
28. Silverberg SG, Haukkamaa M, Arko H, Nilsson CG, Luukkainen T. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. Int J Gynecol Pathol 1986;5:235-241.
29. Sturdee DW, Barlow DH, Ulrich LG, Wells M, Gydesen H, Campbell M, O'Brien K, Vessey M. Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen-progestogen replacement therapy?. Lancet 1994;344:979-982.
30. Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestogen therapy in postmenopausal women. Lancet 1997;349:458-461.
31. Whitehead MI, Townsond PT, Pryse-Davies J, Ryder TA, King RJB. Effects of estrogens and progestins on the biochemistry and morphology of the postmeno-pausal endometrium. N Engl J Med 1981;305:1599-1605.
32. Goldstein SR. Endometrial safety during hormone replacement therapy: comparison of transvaginal sonography and endometrial biopsy. Menopause 1998;5:132-133.
33. Langer RD, Pierce JJ, O'Hanlan KA, Johnson SR, Espeland MA, Trabal JF, Barnabei VM, Merino MJ, Scully RE, for the Postmenopausal Estrogen/Progestin Intervention trial (PEPI). Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. N Eng J Med 1997;337:1792-1798.
34. Hammond CB. Women's concerns with hormone replacement therapy - compliance issues. Fertil Steril 1994;62(Suppl 2):157S-1560S.
35. Hill DA, Weiss NS, La Croix AZ. Adherence to postmenopausal hormone therapy during the year after the initial prescription: a population-based study. Am J Obstet Gynecol 2000;182:270-276.
36. Castelo-Branco C, Figueras F, Sanjuan A, Vincente JJ, Martinez de Osaba MJ, Pons F, Balasch J, Vanrell JA. Long-term compliance with estrogen replacement therapy in surgical postmenopausal women: benefits to bone and analysis of factors associated with discontinuation. Menopause 1999;6:307-311.
37. Ettinger B, Pressman A, Silver P. Effect of age on reasons for initiation and discontinuation of hormone replacement therapy. Menopause 1999;6:282-289.
38. Wildemeersch D, Schacht E, Wildemeersch P. Performance and acceptability of intrauterine release of levonorgestrel with a miniature delivery system for hormonal substitution therapy, contraception and treatment in peri- and postmenopausal women. Maturitas 2002;44:237-245.
39. Suhonen SP, Allonen HO, Lähteenmäki P. Three-year follow-up of the use of a levonorgestrel-releasing intrauterine system in hormone replacement therapy. Acta Obstet Gynecol Scand 1997;76:145-150.
40. Hulley SB, Grady D. The WHI estrogen-alone trial - do things look any better? J Am Med Assoc 2004;291:1769-1771.